دورية أكاديمية
أعرض في EDS

Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies

التفاصيل البيبلوغرافية
العنوان: Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies
المؤلفون: Mari Morita-Fujita, Yasuyuki Arai, Satoshi Yoshioka, Takayuki Ishikawa, Junya Kanda, Tadakazu Kondo, Takashi Akasaka, Yasunori Ueda, Kazunori Imada, Toshinori Moriguchi, Kazuhiro Yago, Toshiyuki Kitano, Akihito Yonezawa, Masaharu Nohgawa, Akifumi Takaori-Kondo, Kyoto Stem Cell Transplantation Group (KSCTG)
المصدر: Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
بيانات النشر: Nature Portfolio, 2020.
سنة النشر: 2020
المجموعة: LCC:Medicine
LCC:Science
مصطلحات موضوعية: Medicine, Science
الوصف: Abstract Since the introduction of leukemia-type induction therapies for T-cell lymphoblastic lymphoma (T-LBL), improvements in the long-term outcomes of T-LBL have been reported. However, indications for and the appropriate timing of hematopoietic stem cell transplantation (HSCT) have not yet been established. Therefore, we performed a multicenter retrospective cohort study of patients with T-LBL treated using leukemia-type initial therapies to compare the outcomes after HSCT at different disease stages. We enrolled 21 patients with T-LBL from a total of 11 centers, and all patients received hyper-CVAD as a leukemia-type initial regimen. HSCT was performed during the CR1/PR1 (standard disease) stage in 11 patients, while it was completed at a later or non-remission (advanced disease) stage in 10 patients. Following HSCT, the overall survival rate was significantly greater in standard disease than in advanced-disease patients (79.5% vs. 30.0% at 5 years; hazard ratio (HR) 5.97; p = 0.03), with trend to the lower incidence of relapse in the former group (27.3% vs. 60.0% at 5 years; HR 2.29; p = 0.19). A prognostic difference was not detected between cases treated with allogeneic and autologous HSCTs. Our study suggests that frontline HSCT may be a feasible treatment option for T-LBL, even in the era of leukemia-type initial therapy.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2045-2322
Relation: https://doaj.org/toc/2045-2322
DOI: 10.1038/s41598-020-78334-x
URL الوصول: https://doaj.org/article/33bb1f49f6f144e8930823840ad60891
رقم الأكسشن: edsdoj.33bb1f49f6f144e8930823840ad60891
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20452322
DOI:10.1038/s41598-020-78334-x